Recently, the Food and Drug Administration of the Ministry of Health and Welfare of Taiwan (FDA) released a report about a new class of hypoglycemic drugs, Glucagon-like peptide-1 (GLP-1) receptor agonists, suspected of causing acute pancreatitis.
Wang Chih-yuan, researcher and chairman of the Taiwanese Association of Diabetes Educators, said that patients who use GLP-1 receptor agonists might also suffer from gastrointestinal discomforts, such as nausea, vomiting, diarrhea, and other side effects. For patients with familial medullary thyroid cancer and multiple endocrine tumor syndrome, Wang strongly advised stopping using anti-diabetic drugs such as GLP-1 receptor agonists.
